Neulasta for intraperitoneal ovarian cancer chemotherapy – pro
The National Comprehensive Cancer Network (NCCN) recommends several options for stage II ovarian cancer, and one of them is IP Taxol/cisplatin. Guideliines recommend myelodi growth factors when risks of febrile neutropenia are greater than 20%.
The risk of febrile neutropenia may be higher for intraperitoneal chemotherapy than for intravenous chemotherapy, but thisw is not securely known or well studied. The kinetis are differetn fomr the invtravenous varian and neutropenia has been reproted to be higher than with teh same agents intravenously. As such,considered acceptable per peer-reviewed medicall literature.
NCCN, Ovarian 2016
Oncology Times:
25 March 2009 – Volume 31 – Issue 6 – pp 9-10
Intraperitoneal Cancer Therapy: Principles and Practice
edited by Wim P. Ceelen, Edward Levine, CRC Press, Oct 22, 2015
TJ Herzog, DK Armstrong, B Goff, DS Dizon, SR Vora,First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer, 2016 – uptodate.com